CN1298708C - 1－（2，6－二氟苄基）－1h－1，2，3－三唑－4－甲酰胺的结晶改良体及其用途 - Google Patents

1－（2，6－二氟苄基）－1h－1，2，3－三唑－4－甲酰胺的结晶改良体及其用途 Download PDF

Info

Publication number
CN1298708C
CN1298708C CNB2004100473675A CN200410047367A CN1298708C CN 1298708 C CN1298708 C CN 1298708C CN B2004100473675 A CNB2004100473675 A CN B2004100473675A CN 200410047367 A CN200410047367 A CN 200410047367A CN 1298708 C CN1298708 C CN 1298708C
Authority
CN
China
Prior art keywords
modification
difluorobenzyl
triazole
methane amide
little less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB2004100473675A
Other languages
English (en)
Chinese (zh)
Other versions
CN1572789A (zh
Inventor
R·波特曼
U·C·霍夫梅尔
A·布克哈德
W·谢尔
M·司泽拉吉维茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4209650&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1298708(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1572789A publication Critical patent/CN1572789A/zh
Application granted granted Critical
Publication of CN1298708C publication Critical patent/CN1298708C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB2004100473675A 1997-06-10 1998-06-08 1－（2，6－二氟苄基）－1h－1，2，3－三唑－4－甲酰胺的结晶改良体及其用途 Expired - Lifetime CN1298708C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH1404/1997 1997-06-10
CH1404/97 1997-06-10
CH140497 1997-06-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB988056755A Division CN1159300C (zh) 1997-06-10 1998-06-08 1-(2,6-二氟苄基)-1h-1,2,3-三唑-4-甲酰胺的结晶改良体及其用作抗癫痫药的用途

Publications (2)

Publication Number Publication Date
CN1572789A CN1572789A (zh) 2005-02-02
CN1298708C true CN1298708C (zh) 2007-02-07

Family

ID=4209650

Family Applications (3)

Application Number Title Priority Date Filing Date
CNB2004100473675A Expired - Lifetime CN1298708C (zh) 1997-06-10 1998-06-08 1－（2，6－二氟苄基）－1h－1，2，3－三唑－4－甲酰胺的结晶改良体及其用途
CN988000113A Expired - Lifetime CN1132820C (zh) 1997-06-10 1998-06-08 药物的结晶改良体
CNB988056755A Expired - Lifetime CN1159300C (zh) 1997-06-10 1998-06-08 1-(2,6-二氟苄基)-1h-1,2,3-三唑-4-甲酰胺的结晶改良体及其用作抗癫痫药的用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN988000113A Expired - Lifetime CN1132820C (zh) 1997-06-10 1998-06-08 药物的结晶改良体
CNB988056755A Expired - Lifetime CN1159300C (zh) 1997-06-10 1998-06-08 1-(2,6-二氟苄基)-1h-1,2,3-三唑-4-甲酰胺的结晶改良体及其用作抗癫痫药的用途

Country Status (36)

Country Link
US (6) US6740669B1 (enExample)
EP (2) EP0994864B1 (enExample)
JP (2) JP3672574B2 (enExample)
KR (2) KR100425656B1 (enExample)
CN (3) CN1298708C (enExample)
AR (4) AR012946A1 (enExample)
AT (2) ATE232852T1 (enExample)
AU (2) AU725517B2 (enExample)
BR (2) BR9804947A (enExample)
CA (3) CA2256013C (enExample)
CO (2) CO4940452A1 (enExample)
CY (1) CY2007014I1 (enExample)
CZ (2) CZ292260B6 (enExample)
DE (3) DE69811500T2 (enExample)
DK (2) DK0994863T3 (enExample)
ES (2) ES2197485T3 (enExample)
FR (1) FR07C0037I2 (enExample)
HU (2) HU226107B1 (enExample)
ID (2) ID21014A (enExample)
IL (2) IL125732A (enExample)
LU (1) LU91345I2 (enExample)
MY (2) MY120156A (enExample)
NL (1) NL300284I2 (enExample)
NO (2) NO329315B1 (enExample)
NZ (2) NZ331371A (enExample)
PE (2) PE79799A1 (enExample)
PL (2) PL192114B1 (enExample)
PT (1) PT994864E (enExample)
RU (2) RU2194041C2 (enExample)
SI (2) SI0994864T1 (enExample)
SK (2) SK283685B6 (enExample)
TR (2) TR199801630T1 (enExample)
TW (2) TW403740B (enExample)
UY (1) UY25844A1 (enExample)
WO (2) WO1998056772A1 (enExample)
ZA (2) ZA984966B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW403740B (en) 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
PE20040538A1 (es) * 2002-05-31 2004-08-30 Schering Corp Polimorfos inhibidores de xantina fosfodiesterasa v
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
US7875284B2 (en) * 2006-03-10 2011-01-25 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
US20090069390A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched rufinamide
NZ591725A (en) * 2008-10-13 2012-09-28 Cipla Ltd PROCESS FOR THE PREPARATION OF RUFINAMIDE which is also known as 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
CN101768124B (zh) * 2008-12-30 2012-01-04 北京本草天源药物研究院 一种药物晶体及其制备方法和用途
IT1395736B1 (it) 2009-08-04 2012-10-19 Dipharma Francis Srl Forme cristalline di rufinamide
US8377973B2 (en) * 2009-09-04 2013-02-19 Tactical Therapeutics Inc Compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations
EP2465853A1 (en) * 2010-12-14 2012-06-20 Laboratorios Lesvi, S.L. Polymorph of rufinamide and process for obtaining it
WO2011135105A1 (en) * 2010-04-30 2011-11-03 Laboratorios Lesvi, S.L. Improved process for preparing rufinamide intermediate
ITMI20110718A1 (it) 2011-04-29 2012-10-30 Dipharma Francis Srl Procedimento per la purificazione di rufinamide
US10206874B2 (en) 2012-07-20 2019-02-19 Hetero Research Foundation Rufinamide solid dispersion
WO2021099481A1 (en) 2019-11-20 2021-05-27 Medichem, S.A. Solid composition containing rufinamide

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346097A (en) * 1980-09-30 1982-08-24 Warner-Lambert Company Method for treating convulsions with pyrazole-4-carboxamide derivatives
US4511572A (en) * 1983-03-18 1985-04-16 The University Of Kentucky Research Foundation Triazoline anticonvulsant drugs
US4789680A (en) * 1982-12-23 1988-12-06 Ciba-Geigy Corporation Aralkyltriazole compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992378A (en) 1973-12-26 1976-11-16 Eli Lilly And Company Fluoralkyl quinoxadinediones
US4156734A (en) 1976-02-13 1979-05-29 Merck & Co., Inc. Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid
GB1511195A (en) 1976-10-18 1978-05-17 Ici America Inc Triazole derivatives
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
FI834666A7 (fi) 1982-12-23 1984-06-24 Ciba Geigy Ag Foerfarande foer framstaellning av nya aralkyltriazolfoereningar.
PH22568A (en) * 1985-04-18 1988-10-17 Ciba Geigy Ag Fluorinated benzyl triazoles and pharmaceutical compositions containing the same
CA2002864C (en) 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
JPH02214504A (ja) 1989-02-15 1990-08-27 Nissan Chem Ind Ltd 光学活性キノキサリン化合物の晶析法
JPH04506967A (ja) 1989-07-27 1992-12-03 ジー．ディー．サール　アンド　カンパニー 高血圧症治療用腎選択性生成物
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
AU656154B2 (en) 1990-11-06 1995-01-27 Astellas Pharma Inc. Fused pyrazine derivative
JP2753911B2 (ja) 1991-12-06 1998-05-20 キッセイ薬品工業株式会社 Ｎ−ｔｅｒｔ−ブチル−１−メチル−３，３−ジフェニルプロピルアミン塩酸塩の結晶多形およびその製造方法
DE4217952A1 (de) 1992-05-30 1993-12-02 Basf Ag Chinoxalin-2,3(1H,4H)-dione
US5248699A (en) 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5631373A (en) 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
GB9418443D0 (en) 1994-09-13 1994-11-02 Pfizer Ltd Therapeutic agents
GB9419318D0 (en) 1994-09-24 1994-11-09 Pfizer Ltd Therapeutic agents
CN1072215C (zh) 1995-02-22 2001-10-03 赫彻斯特药品和化学品公司 无定形吡咯他尼、吡咯他尼多晶型物,其制备方法和用途
SK283990B6 (sk) * 1996-07-11 2004-07-07 Novartis Ag Spôsob prípravy 1-substituovaných 4-kyano-1,2,3-triazolov, 4-kyano-1-(2,6-difluórbenzyl)-1H-1,2,3-triazol
TW403740B (en) 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346097A (en) * 1980-09-30 1982-08-24 Warner-Lambert Company Method for treating convulsions with pyrazole-4-carboxamide derivatives
US4789680A (en) * 1982-12-23 1988-12-06 Ciba-Geigy Corporation Aralkyltriazole compounds
US4511572A (en) * 1983-03-18 1985-04-16 The University Of Kentucky Research Foundation Triazoline anticonvulsant drugs

Also Published As

Publication number Publication date
CZ253398A3 (cs) 1999-04-14
KR19990087835A (ko) 1999-12-27
JP2000516259A (ja) 2000-12-05
US20060116520A1 (en) 2006-06-01
KR19990087836A (ko) 1999-12-27
NZ331371A (en) 2000-08-25
HK1028241A1 (en) 2001-02-09
ID21014A (id) 1999-04-08
DE69811500T2 (de) 2004-04-01
US7750028B2 (en) 2010-07-06
HK1028242A1 (en) 2001-02-09
AR061004A2 (es) 2008-07-30
DK0994864T3 (da) 2003-07-21
LU91345I2 (fr) 2007-09-04
SI0994863T1 (en) 2003-08-31
IL125733A0 (en) 1999-04-11
HUP0000798A3 (en) 2000-10-30
AR012946A1 (es) 2000-11-22
US20030125568A1 (en) 2003-07-03
CA2256013A1 (en) 1998-12-17
NO329315B1 (no) 2010-09-27
CN1132820C (zh) 2003-12-31
TW403740B (en) 2000-09-01
CY2007014I2 (el) 2009-11-04
ZA984967B (en) 1999-01-11
DE69811500D1 (de) 2003-03-27
WO1998056772A1 (en) 1998-12-17
NO329314B1 (no) 2010-09-27
CO4940448A1 (es) 2000-07-24
SK283685B6 (sk) 2003-12-02
FR07C0037I2 (enExample) 2008-05-16
TR199801631T1 (xx) 1999-06-21
MY125854A (en) 2006-08-30
US6740669B1 (en) 2004-05-25
US20040167186A1 (en) 2004-08-26
PL330764A1 (en) 1999-05-24
DE69813560T2 (de) 2004-02-05
ATE232852T1 (de) 2003-03-15
TW526195B (en) 2003-04-01
CA2256013C (en) 2007-10-16
SK283734B6 (sk) 2003-12-02
WO1998056773A1 (en) 1998-12-17
CA2614926A1 (en) 1998-12-17
NO983666L (no) 1998-12-17
NO983667L (no) 1998-12-17
ZA984966B (en) 1999-01-11
MY120156A (en) 2005-09-30
IL125732A (en) 2002-12-01
PL192114B1 (pl) 2006-08-31
NL300284I2 (nl) 2007-11-01
PL330798A1 (en) 1999-06-07
PL191943B1 (pl) 2006-07-31
EP0994864A1 (en) 2000-04-26
KR100409168B1 (ko) 2004-01-31
TR199801630T1 (xx) 1999-06-21
CN1217716A (zh) 1999-05-26
HK1028031A1 (en) 2001-02-02
CZ292481B6 (cs) 2003-09-17
JP3672574B2 (ja) 2005-07-20
CA2256015A1 (en) 1998-12-17
CN1159300C (zh) 2004-07-28
EP0994863B1 (en) 2003-02-19
SK109398A3 (en) 1998-12-02
JP2000516258A (ja) 2000-12-05
HU225153B1 (en) 2006-07-28
EP0994863A1 (en) 2000-04-26
HUP0002113A3 (en) 2002-09-30
AU8437198A (en) 1998-12-30
CY2007014I1 (el) 2009-11-04
KR100425656B1 (ko) 2004-05-17
HUP0000798A2 (hu) 2000-10-30
AU8437298A (en) 1998-12-30
ES2192779T3 (es) 2003-10-16
IL125732A0 (en) 1999-04-11
US20100310655A1 (en) 2010-12-09
AR012945A1 (es) 2000-11-22
CN1259127A (zh) 2000-07-05
HU226107B1 (en) 2008-04-28
RU2194041C2 (ru) 2002-12-10
US8076362B2 (en) 2011-12-13
DE69813560D1 (de) 2003-05-22
AU725528B2 (en) 2000-10-12
US20010037029A1 (en) 2001-11-01
ES2197485T3 (es) 2004-01-01
BR9804946A (pt) 1999-08-24
SI0994864T1 (en) 2003-10-31
LU91345I9 (enExample) 2018-12-31
NL300284I1 (nl) 2007-10-01
NO983667D0 (no) 1998-08-11
US6455556B2 (en) 2002-09-24
FR07C0037I1 (enExample) 2007-08-17
SK109498A3 (en) 1998-12-02
JP3672575B2 (ja) 2005-07-20
CZ292260B6 (cs) 2003-08-13
HUP0002113A2 (hu) 2001-02-28
PE79799A1 (es) 1999-09-03
EP0994864B1 (en) 2003-04-16
CZ253498A3 (cs) 1999-04-14
ID27660A (id) 2001-04-19
CA2256015C (en) 2008-06-03
BR9804947A (pt) 1999-08-24
AR061005A2 (es) 2008-07-30
CA2614926C (en) 2010-02-09
PE80999A1 (es) 1999-09-06
RU2198167C2 (ru) 2003-02-10
NZ331370A (en) 2000-08-25
NO983666D0 (no) 1998-08-11
DK0994863T3 (da) 2003-05-26
IL125733A (en) 2002-12-01
UY25844A1 (es) 2001-08-27
CN1572789A (zh) 2005-02-02
PT994864E (pt) 2003-07-31
DE122007000051I1 (de) 2007-11-08
DE122007000051I2 (de) 2009-02-19
CO4940452A1 (es) 2000-07-24
AU725517B2 (en) 2000-10-12
ATE237599T1 (de) 2003-05-15

Similar Documents

Publication Publication Date Title
CN1298708C (zh) 1－（2，6－二氟苄基）－1h－1，2，3－三唑－4－甲酰胺的结晶改良体及其用途
TW589310B (en) Crystalline antifungal polymorph
BG98248A (bg) Хинуклидинови производни
EP0407342A2 (de) Neue Pyrimidin Derivate
EP0415886A2 (de) Aza-Verbindungen
EP0475898A1 (de) Azacyclische Verbindungen
JPWO1994014769A1 (ja) Ｎ−置換インドール誘導体
CA1339803C (en) Dideoxydidehydrocarbocyclic nucleosides
JPS601161A (ja) Ｎ−ホルミル、ｎ−ヒドロキシメチル−３−フエノキシ−１−アゼチジンカルボキサミド、その製造方法及びそれからなる鎮痙剤
JPS58225086A (ja) 放射線治療または化学療法に有用な化合物
CN115066425B (zh) Jak抑制剂在制备治疗jak激酶相关疾病药物中的应用
JPS61210085A (ja) 免疫調節剤として有効なイミダゾ〔４，５−ｆ〕キノリン
JP2009235088A (ja) ５−ヒドロキシ−１−メチルヒダントイン結晶の製造方法
FR2580642A1 (fr) 5-pyrimidinecarboxamides et traitement de la leucemie et des tumeurs en les utilisant
CN112812099B (zh) 一种用于治疗消化性溃疡的化合物及其制法和用途
CN1058020A (zh) 诺贝拉斯丁柠檬酸盐
CN85108245A (zh) 新晶型苯并噻嗪二氧化物盐的制备方法
CN113979931A (zh) 一种吡啶3-胺衍生物及其制备方法和应用
CN116710460A (zh) 联苯衍生物及其应用
CN1136201C (zh) 药理活性的对映体及其制备方法
DE3314196A1 (de) Heterocyclylaether
CN105992769A (zh) 一种钠-葡萄糖协同转运蛋白2抑制剂的l-脯氨酸复合物、其一水合物及晶体
JPH0925268A (ja) ２−ニトロイミダゾール誘導体
CA1210001A (en) Semicarbazides, the preparation and use thereof
CN119790056A (zh) 三并环类衍生物、药物组合物以及应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: NOVARTIS CO., LTD.

Free format text: FORMER NAME: NOVARTIS AG

CP01 Change in the name or title of a patent holder

Address after: Basel

Patentee after: Novartis Ag

Address before: Basel

Patentee before: Novartis AG

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20070207